Shouldn't use titles like that to be honest. A single study is a single study, not a fact. There are continuous studies regarding immunosupressants and many that contradict that study.
I don't think it's good to just link one single study and then make a title like that. There have been many that showed an increased risk, there have been some that did not. My guess is that there is probably an increased risk based on the volume of studies that do show an increased risk.
The question should also be asked, what happens to someone who is on TNF-alpha blocker and gets a cancer. Not just onset matters. People on TNF-alpha blockers who get cancer, especially combo therapy, often have rapidly progressing cancers, because of the fact they were on TNF-alpha blockers.
TNF-alpha stands for
Tumor necrosis factor alpha, it didn't get that name by accident, it's directly involved in killing of cancers.
http://www.ncbi.nlm.nih.gov/pubmed/24328939
Melanoma Associated with TNFα Inhibitors: a Research on Adverse Drug events And Reports (RADAR) Project.
Nardone B, Hammel JA, Raisch DW, Weaver LL, Schneider D, West DP.
2013 Dec
BACKGROUND:
Tumor necrosis factor-alpha inhibitors (TNFαIs) are used for treatment of inflammatory disorders. There is evidence linking these agents with occurrence of malignancies. For four out of five TNFαIs the Food and Drug Administration (FDA) label states, "melanoma has been reported in patients treated with these agents."
OBJECTIVES:
Determine whether a statistically-significant association exists between administration of TNFαIs and development of malignant melanoma.
METHODS:
We searched the FDA Adverse Events Reporting System (FAERS) database for terms related to melanoma and TNFαIs for detection of safety signals. We also searched a large urban academic electronic medical record (EMR) database for which we calculated the relative risk (RR) of melanoma in subjects exposed to TNFαIs vs. non-exposed subjects.
RESULTS:
There were 972 reports of melanoma associated with a TNFαIs identified in the FAERS database, with 69 reports among individuals using more than one TNFαI. A safety signal was detected for infliximab (I) golimumab (G), etanercept (E), and adalimumab (A). Cetrolizumab pegol (CP) had no detectible safety signal. For TNFαIs as a class of drugs, a safety signal was detectable in the FAERS database, and RR was significant in the EMR database. For the EMR cohort, 6,045 patients were exposed to TNFαIs and 35 cases of melanoma were detected. Significance for RR was detected for A (RR = 1.8, p = 0.02) and E (RR 2.35, p = 0.0004).
CONCLUSIONS:
We identified a significant association between exposure to TNFαIs and malignant melanoma in two different analyses. Our findings add to existing evidence linking these agents with the occurrence of malignant melanoma. Additional investigations are required to further explore this association and the risk of melanoma with TNFαI therapy.